Adenoviruses as gene/vaccine delivery vectors: Promises and pitfalls

Expert Opinion on Biological Therapy

Volumn 15, Issue 3, 2015, Pages 337-351

  Appaiahgari, Mohan Babu ^a   Vrati, Sudhanshu ^a  

^a Vaccine and Infectious Disease Research Center Translational Health Science and Technology Inst   (India)

Author keywords

Adenovirus; Gene therapy; Hexon; Immunogenicity; Oncolytic adenovirus; PEGylation; Penton base; Protein IX; Tissue tropism; Vaccination

Indexed keywords

ADENOVIRUS PROTEIN; ADENOVIRUS VECTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; DRUG CARRIER; LONTUCIREV; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ADENO ASSOCIATED VIRUS; ADENOVIRIDAE; BLOOD GROUP; CELLS BY BODY ANATOMY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GENE TARGETING; GENE VECTOR; HUMAN; HUMAN ADENOVIRUS 5; IMMUNE RESPONSE; IMMUNITY; IN VIVO STUDY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); REVIEW; SEROTYPE; TISSUE CHARACTERIZATION; TRANSGENE; TRANSIENT EXPRESSION; TUMOR SUPPRESSOR GENE; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; ADMINISTRATION AND DOSAGE; ANIMAL; DRUG DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; GENETICS; PROCEDURES; TRENDS;

ADENOVIRIDAE;

ADENOVIRIDAE; ANIMALS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; VIRAL VACCINES;

EID: 84923084694     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.993374     Document Type: Review

References (98)

1. Giacca M, Zacchigna S. Virus-mediated gene delivery for human gene therapy. J Control Release 2012;161:377-88
2. Russell WC. Adenoviruses: update on structure and function. J Gen Virol 2009;90:1-20
3. Martin CS. Latest insights on adenovirus structure and assembly. Viruses 2012;4:847-77
4. Bradley RR, Lynch DM, Iampietro MJ, et al. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol 2012;86:625-9
5. Frahm N, deCamp AC, Friedrich DP, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012;122:359-67
6. Edelstein M. Gene therapy clinical trials worldwide-Online library by Journal of Gene Medicine. John Wiley and Sons Ltd; 2014. http://www.wiley.com/legacy/wileychi/genmed/clinical/
7. Khare R, Chen CY, Weaver EA, Barry MA. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 2011;11:241-58
8. Small JC, Ertl HC. Viruses-from pathogens to vaccine carriers. Curr Opin Virol 2011;1:241-5
9. Zaiss AK, Machado HB, Herschman HR. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 2009;108:778-90
10. Lanuti M, Gao GP, Force SD, et al. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum Gene Ther 1999;10:463-75
11. Dormond E, Perrier M, Kamen A. From the first to the third generation adenoviral vector: what parameters are governing the production yield? Biotechnol Adv 2009;27:133-44
12. Vetrini F, Ng P. Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses 2010;2:1886-917
13. Cao H, Yang T, Li XF, et al. Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression. Gene Ther 2011;18:173-81
14. Ahn M, Gamble A, Witting SR, et al. Vector and helper genome rearrangements occur during production of helper-dependent adenoviral vectors. Hum Gene Ther Methods 2013;24:1-10
15. Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007;28:42-58
16. Jia H, Kling J. China offers alternative gateway for experimental drugs. Nat Biotechnol 2006;24:117-18
17. Toth K, Wold WS. Increasing the efficacy of oncolytic adenovirus vectors. Viruses 2010;2:1844-66
18. Pol J, Bloy N, Obrist F, et al. Trial Watch: oncolytic viruses for cancer therapy. Oncoimmunology 2014;3:e28694
19. Hemminki A. Oncolytic immunotherapy: where are we clinically? Scientifica (Cairo) 2014;2014:862925
20. Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010;70:4297-309
21. Pesonen S, Diaconu I, Kangasniemi L, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res 2012;72:1621-31
22. Pesonen S, Diaconu I, Cerullo V, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012;130:1937-47
23. Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010;18:1874-84
24. Hemminki O, Diaconu I, Cerullo V, et al. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther 2012;20:1821-30
25. Liikanen I, Ahtiainen L, Hirvinen ML, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 2013;21:1212-23
26. U.S. National Institutes of Health. Registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Available from: http://www. clinicaltrials.gov/[Accessed 19 August 2014]
27. Middleton PG, Alton EW. Gene therapy for cystic fibrosis: which postman, which box? Thorax 1998;53:197-9
28. Perricone MA, Morris JE, Pavelka K, et al. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum Gene Ther 2001;12:1383-94
29. Rosenecker J, Harms KH, Bertele RM, et al. Adenovirus infection in cystic fibrosis patients: implications for the use of adenoviral vectors for gene transfer. Infection 1996;24:5-8
30. Yla-Herttuala S. Cardiovascular gene therapy with vascular endothelial growth factors. Gene 2013;525:217-19
31. Lahteenvuo JE, Lahteenvuo MT, Kivela A, et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1-and neuropilin receptor-1-dependent mechanisms. Circulation 2009;119:845-56
32. Priddy FH, Brown D, Kublin J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008;46:1769-81
33. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93
34. Peters W, Brandl JR, Lindbloom JD, et al. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans. Vaccine 2013;31:1752-8
35. Asmuth DM, Brown EL, DiNubile MJ, et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J Infect Dis 2010;201:132-41
36. Tamminga C, Sedegah M, Regis D, et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 2011;6:e25868
37. Peiperl L, Morgan C, Moodie Z, et al. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS One 2010;5:e13579
38. Gurwith M, Lock M, Taylor EM, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013;13:238-50
39. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012;4:115ra1
40. Abel B, Tameris M, Mansoor N, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 2010;181:1407-17
41. Hoft DF, Blazevic A, Stanley J, et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 2012;30:2098-108
42. O'Hara GA, Duncan CJ, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012;205:772-81
43. Ogwang C, Afolabi M, Kimani D, et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One 2013;8:e57726
44. Sheehy SH, Duncan CJ, Elias SC, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 2012;20:2355-68
45. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-58
46. Xu Z, Tian J, Smith JS, Byrnes AP. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol 2008;82:11705-13
47. Carlisle RC, Di Y, Cerny AM, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009;113:1909-18
48. Othman M, Labelle A, Mazzetti I, et al. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 2007;109:2832-9
49. Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010;28:950-7
50. Appaiahgari MB, Pandey RM, Vrati S. Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines. Clin Vaccine Immunol 2007;14:1053-5
51. Barouch DH, Kik SV, Weverling GJ, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011;29:5203-9
52. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010;5:357-61
53. Benlahrech A, Harris J, Meiser A, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 2009;106:19940-5
54. Majhen D, Calderon H, Chandra N, et al. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther 2014;25:301-17
55. Parker AL, Waddington SN, Nicol CG, et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 2006;108:2554-61
56. Xu Z, Qiu Q, Tian J, et al. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 2013;19:452-7
57. Zhang Y, Bergelson JM. Adenovirus receptors. J Virol 2005;79:12125-31
58. Bradshaw AC, Parker AL, Duffy MR, et al. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog 2010;6:e1001142
59. Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010;18:243-50
60. Kimball KJ, Preuss MA, Barnes MN, et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 2010;16:5277-87
61. Liikanen I, Monsurro V, Ahtiainen L, et al. Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol Ther 2011;19:1858-66
62. Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005;11:66-79
63. Wortmann A, Vohringer S, Engler T, et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther 2008;16:154-62
64. Weaver EA, Nehete PN, Buchl SS, et al. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One 2009;4:e5059
65. Appaiahgari MB, Saini M, Rauthan M, et al. Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect 2006;8:92-104
66. Lambe T, Carey JB, Li Y, et al. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci Rep 2013;3:1443
67. Coughlan L, Alba R, Parker AL, et al. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2010;2:2290-355
68. Doronin K, Shashkova EV, May SM, et al. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 2009;20:975-88
69. Di Paolo NC, van Rooijen N, Shayakhmetov DM. Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver. Mol Ther 2009;17:675-84
70. Kuhlmann KF, Van Geer MA, Bakker CT, et al. Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma. Cancer Gene Ther 2009;16:585-97
71. Behr M, Kaufmann JK, Ketzer P, et al. Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds. PLoS One 2014;9:e95723
72. Short JJ, Rivera AA, Wu H, et al. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol Cancer Ther 2010;9:2536-44
73. Zhang Z, Krimmel J, Zhang Z, et al. Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model. Hum Gene Ther 2011;22:1137-42
74. Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007;7:189-204
75. MacLeod SH, Elgadi MM, Bossi G, et al. HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice. Cancer Gene Ther 2012;19:888-98
76. Matsui H, Sakurai F, Katayama K, et al. A targeted adenovirus vector displaying a human fibronectin type III domain-based monobody in a fiber protein. Biomaterials 2013;34:4191-201
77. Vellinga J, Van der HS, Hoeben RC. The adenovirus capsid: major progress in minor proteins. J Gen Virol 2005;86:1581-8
78. Meulenbroek RA, Sargent KL, Lunde J, et al. Use of adenovirus protein IX (pIX) to display large polypeptides on the virion-generation of fluorescent virus through the incorporation of pIX-GFP. Mol Ther 2004;9:617-24
79. Gorman JJ, Wallis TP, Whelan DA, et al. LH3, a "homologue" of the mastadenoviral E1B 55-kDa protein is a structural protein of atadenoviruses. Virology 2005;342:159-66
80. Harris JD, Roberts ML, Perumal D, et al. Efficient liver-directed gene transfer by in situ generation of retroviral vector from adenoviral templates. In Vivo 2009;23:885-93
81. Sitaraman V, Hearing P, Ward CB, et al. Computationally designed adeno-associated virus (AAV) Rep 78 is efficiently maintained within an adenovirus vector. Proc Natl Acad Sci USA 2011;108:14294-9
82. Huang S, Kamihira M. Development of hybrid viral vectors for gene therapy. Biotechnol Adv 2013;31:208-23
83. Murphy SJ, Chong H, Bell S, et al. Novel integrating adenoviral/retroviral hybrid vector for gene therapy. Hum Gene Ther 2002;13:745-60
84. Zheng C, Cotrim AP, Nikolov N, et al. A novel hybrid adenoretroviral vector with more extensive E3 deletion extends transgene expression in submandibular glands. Hum Gene Ther Methods 2012;23:169-81
85. Henckaerts E, Linden RM. Adeno-associated virus: a key to the human genome? Future Virol 2010;5:555-74
86. Hausl MA, Zhang W, Muther N, et al. Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol Ther 2010;18:1896-906
87. Chalberg TW, Portlock JL, Olivares EC, et al. Integration specificity of phage phiC31 integrase in the human genome. J Mol Biol 2006;357:28-48
88. Ramachandran M, Yu D, Wanders A, et al. An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors. Mol Ther 2013;21:2008-18
89. Wold WS, Toth K. Chapter three-Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv Cancer Res 2012;115:69-92
90. Woller N, Gurlevik E, Ureche CI, et al. Oncolytic viruses as anticancer vaccines. Front Oncol 2014;4:188
91. Bressy C, Benihoud K. Association of oncolytic adenoviruses with chemotherapies: an overview and future directions. Biochem Pharmacol 2014;90:97-106
92. Medina-Kauwe LK. Development of adenovirus capsid proteins for targeted therapeutic delivery. Ther Deliv 2013;4:267-77
93. Galinier R, Gout E, Lortat-Jacob H, et al. Adenovirus protein involved in virus internalization recruits ubiquitin-protein ligases. Biochemistry 2002;41:14299-305
94. Agadjanian H, Ma J, Rentsendorj A, et al. Tumor detection and elimination by a targeted gallium corrole. Proc Natl Acad Sci USA 2009;106:6105-10
95. Hwang JY, Lubow J, Chu D, et al. A mechanistic study of tumor-targeted corrole toxicity. Mol Pharm 2011;8:2233-43
96. Hwang JY, Lubow DJ, Chu D, et al. Photoexcitation of tumor-targeted corroles induces singlet oxygen-mediated augmentation of cytotoxicity. J Control Release 2012;163:368-73
97. Hwang JY, Lubow DJ, Sims JD, et al. Investigating photoexcitation-induced mitochondrial damage by chemotherapeutic corroles using multimode optical imaging. J Biomed Opt 2012;17:015003
98. Li J, Liu H, Li L, et al. The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma. Oncol Rep 2013;29:895-902